International Edition
Latest News
Technology

TARGET-D Trial: Vitamin D Did Not Significantly Reduce Major Cardiovascular Events Post-Heart Attack

Vitamin D supplements failed to lower the overall rate of major cardiovascular events in patients who had recently suffered a heart attack, according to results from the TARGET-D trial published in the American Heart Journal. The study randomized…

TARGET-D Trial: Vitamin D Did Not Significantly Reduce Major Cardiovascular Events Post-Heart Attack

Vitamin D supplements failed to lower the overall rate of major cardiovascular events in patients who had recently suffered a heart attack, according to results from the TARGET-D trial published in the American Heart Journal.

The study randomized 630 patients within a month of myocardial infarction to either usual care or a titrated vitamin D3 regimen targeting a 25-hydroxyvitamin D level of at least 40 ng/mL.

After a median follow-up of 4.2 years, 15.7% of the treatment group experienced a major adverse cardiovascular event — defined as heart attack, stroke, heart-failure hospitalization or cardiovascular death — compared with 18.4% in the usual-care group, a hazard ratio of 0.85 that was not statistically significant (95% CI 0.58–1.24, p = 0.40).

The trial, led by researchers at Intermountain Healthcare, was designed to test whether correcting low vitamin D levels — rather than simply assigning a fixed dose — could reduce cardiovascular risk.

Previous large trials such as VITAL, which gave 2,000 IU daily to more than 25,000 generally healthy adults regardless of baseline levels, found no benefit on major cardiovascular events. In VITAL, 55.1% of participants already had 25(OH)D levels at or above 30 ng/mL before supplementation began.

In TARGET-D, 87.0% of enrollees started with 25(OH)D at or below 40 ng/mL, and the median baseline level was 25 ng/mL. Doses were adjusted every three months until the target was reached or the maximum protocol dose was given. Despite the treat-to-target design, 21% of participants in the intervention arm never achieved the 40 ng/mL threshold.

Isolated reduction in recurrent heart attacks

When the investigators examined the individual components of the primary endpoint, recurrent myocardial infarction occurred in 3.8% of the vitamin D group versus 7.9% of the usual-care group (HR 0.48, 95% CI 0.24–0.96, p = 0.03). The reduction did not persist in a per-protocol analysis restricted to participants who actually reached the 40 ng/mL target, where the hazard ratio was 0.69 (95% CI 0.33–1.44, p = 0.15).

The trial was stopped early because of the COVID-19 pandemic, leaving it underpowered relative to its original sample-size calculation. The authors also did not adjust for multiple comparisons across the primary endpoint, its components, and more than a dozen secondary outcomes, raising the possibility that the heart-attack finding arose by chance.

Trends in the opposite direction that were not statistically significant appeared for heart-failure hospitalization (4.2% vs 3.5%, HR 1.21) and stroke (1.6% vs 0.9%, HR 1.69), though confidence intervals were wide.

Open-label design limits causal inference

TARGET-D did not use a placebo; the control group received usual care without blinding. The open-label design introduces performance bias — clinicians may have managed patients differently based on group assignment — and makes it impossible to separate a biological effect of vitamin D from the effects of additional clinical contact and dose-titration visits.

Context from earlier trials

VITAL, the largest completed vitamin D cardiovascular outcomes trial, found no effect on major cardiovascular events (HR 0.97) or on myocardial infarction specifically (HR 0.96, 95% CI 0.78–1.19). The D-Health trial reported a modest reduction in heart attacks (HR 0.81, 95% CI 0.67–0.98) but no difference in the composite cardiovascular endpoint. The ViDA and DO-HEALTH trials likewise showed no benefit on major cardiovascular outcomes.

A 2022 review in Nature Reviews Endocrinology concluded that vitamin D supplementation of vitamin D–replete adults does not prevent cardiovascular events, falls, or progression to type 2 diabetes. TARGET-D is the first randomized trial to test a treat-to-target strategy in a post–myocardial infarction population.

What remains unanswered

Whether achieving and maintaining a 25(OH)D level of 40 ng/mL or higher causally reduces recurrent heart attacks in patients with established coronary disease is unresolved.

A larger, placebo-controlled, blinded treat-to-target trial with adequate power and pre-specified multiplicity adjustment would be needed to confirm or refute the signal seen in TARGET-D. Current guidelines do not recommend routine vitamin D screening or supplementation for cardiovascular prevention in the general population or in patients with existing heart disease.

“encourage people with heart disease to discuss vitamin D blood testing and targeted dosing with their health care professionals to meet their individual needs,” the lead author of the TARGET-D trial said.

About the author: Technology Desk

Technology Desk at Archynewsy.